UNSPSC 51102871: Polymyxin b/trimethoprim

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP219. This VA Drug Class (OP219) classifies this compound as belonging to the group ANTI-INFECTIVE, TOPICAL OPHTHALMIC, OTHER.

UNSPSC 51102871 Polymyxin b/trimethoprim is a Commodity code that nominally refers to a specific antibiotic combination, but recent state and local procurement activity under this code shows little relevant alignment with the code's pharmaceutical scope. The most recent opportunities posted under 51102871 include acquisitions of naloxone and drug deactivation systems, medical and first aid supplies for fire-rescue operations, generic multi-source pharmaceuticals through cooperative purchasing, and a Texas HHS information-gathering initiative on direct-to-manufacturer prescription programs. These solicitations span emergency medical supplies, broad-spectrum pharmaceutical procurement, and pharmacy benefit restructuring rather than trimethoprim-based antibiotics specifically. State and local issuing bodies pursuing opportunities under this code include county health departments (Seminole County, Florida), municipal fire departments (Tampa), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving Minnesota, Oregon, and other participating jurisdictions).

Recent activity concentrates in Florida, Texas, and Minnesota, with MMCAP's multi-state cooperative model extending reach across participating states. Representative opportunities include Seminole County's IFB 60459723LAS (due July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries), the City of Tampa's IFB 26P00145 (due March 13, 2026, for 169 line items of medical and first aid supplies for the Fire Department Rescue Division, estimated at $700,000 and restricted to certified Small Local Business Enterprises with a 5 percent bid discount), MMCAP's RFP S1070000015802 (due March 26, 2026, for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with awards effective July 1, 2026), and Texas HHS's RFI HHS0017013 (posted April 3, 2026, exploring vendor capabilities for direct-to-manufacturer prescription programs). The code shows activity but exhibits significant mismatch between its nominal pharmaceutical scope and the actual emergency-response and broad-spectrum procurement work being solicited.